e-learning
resources
Munich 2014
Wednesday, 10.09.2014
Antibiotics, antifungals and other therapeutic options
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid
P. aeruginosa
isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment
S. Obertegger, G. Weskott, P. Surdakowski, M. Glenschek-Sieberth (Wuppertal, Germany)
Source:
International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Session:
Antibiotics, antifungals and other therapeutic options
Session type:
Poster Discussion
Number:
4694
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Obertegger, G. Weskott, P. Surdakowski, M. Glenschek-Sieberth (Wuppertal, Germany). Efficacy of ciprofloxacin against resistant mucoid or non-mucoid
P. aeruginosa
isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment. Eur Respir J 2014; 44: Suppl. 58, 4694
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort
Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives
Year: 2015
Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients
Source: International Congress 2015 – Advances from translational research in respiratory infections
Year: 2015
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and
Pseudomonas aeruginosa
infection
Source: Eur Respir J 2005; 26: Suppl. 49, 620s
Year: 2005
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa
Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections
Year: 2014
Patients with no cystic fibrosis bronchiectasis colonized by
pseudomonas aeruginosa
: Role of inhaled colistin
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017
Daily versus weekly azithromycin in cystic fibrosis patients
Source: Eur Respir J 2007; 30: 487-495
Year: 2007
Azithromycin in chronic respiratory infections with
pseudomonas aeruginosa
in patients without cystic fibrosis
Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Year: 2008
Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015
Nebulized antibiotics in patients with non-cystic fibrosis bronchiectasis ans chronic pseudomonas aeruginosa infection
Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Year: 2011
Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015
Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
Source: Eur Respir J 2013; 41: 1107-1115
Year: 2013
Eradication regime of methicillin resistant staphylococcus aureus lung infection in cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
Pseudomonas aeruginosa infections
Source: Respipedia Article
Year: 2018
Tobramycin by aerosol (Toby®) eradicates
Pseudomonas aeruginosa
resistant to Tobramycin
i.v.
in patients with infected bronchiectasis
Source: Eur Respir J 2001; 18: Suppl. 33, 542s
Year: 2001
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis},
Source: Eur Respir J 2012; 40: 1014-1023
Year: 2012
Results of Tobramycin inhalation therapy in patients with noncystic fibrosis bronchiectasis with Pseudomonas Aeruginosa colonization: Real Life Management
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept